💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Fortis Healthcare Limited is an India-based integrated healthcare service provider. The Company is primarily engaged in the business of healthcare services. Its segment includes the Healthcare business and the Diagnostics business. The healthcare business includes inpatient…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, steadily growing business, reasonably priced.
Fortis Healthcare is scored on the pharma / healthcare framework. It keeps a healthy 11.6% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.50× reported profit. Free cash flow is worth about 0.1% of its market value.
Over the last 3 years revenue compounded at 13%/yr and profit at 19%/yr. Book value has grown 8%/yr. Return on equity is a modest 9.9%. In the latest quarter profit grew 1% versus the prior quarter.
At 56× earnings, the stock sits at the 29th percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price already implies ~23%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 54.51 | 75.46 | better |
| P/B | 5.53 | 3.5 | worse |
| EV/EBITDA | 29.38 | 19.83 | worse |
| ROE | 9.91 | — | — |
| ROCE | 12.56 | 10.78 | better |
| ROA | 6.47 | 3.84 | better |
| Quick Ratio | 0.8 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Apollo Hospitals | 52.0 | 11.4 | 21.1% |
| Max Healthcare | 65.9 | 8.0 | 12.2% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
Revenue has grown every year across all 4 financial years shown. 13% CAGR over 3 years — steady double-digit compounder.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (19% vs 13%) — margin expansion is at work. The latest year saw a +31% swing — check if it's a one-off or structural.
Operating margin has expanded from 13% to 15% — the business is keeping more of each rupee earned.
ROE at 10% — modest; the capital isn't working hard. Low variance across years — a predictable business that earns steadily on its equity base.
EPS has grown every year — each share earns more than the last, consistently. EPS outpaced profit growth — possible buybacks are concentrating earnings into fewer shares. 21% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.5× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 8% sequentially — momentum is building.
Quarterly margins are compressing (14% → 11%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 31.2% — dispersed ownership; institutional flows drive the stock. FIIs trimmed 4.6pp — foreign money is rotating out. MF holding up 2.7pp — domestic institutional discovery underway.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.